| Literature DB >> 30736486 |
Parisa Eslami1, Filippo Rossi2, Stefano Fedeli3.
Abstract
Considering nanogels, we have focused our attention on hybrid nanosystems for drug delivery and biomedical purposes. The distinctive strength of these structures is the capability to join the properties of nanosystems with the polymeric structures, where versatility is strongly demanded for biomedical applications. Alongside with the therapeutic effect, a non-secondary requirement of the nanosystem is indeed its biocompatibility. The importance to fulfill this aim is not only driven by the priority to reduce, as much as possible, the inflammatory or the immune response of the organism, but also by the need to improve circulation lifetime, biodistribution, and bioavailability of the carried drugs. In this framework, we have therefore gathered the hybrid nanogels specifically designed to increase their biocompatibility, evade the recognition by the immune system, and overcome the self-defense mechanisms present in the bloodstream of the host organism. The works have been essentially organized according to the hybrid morphologies and to the strategies adopted to fulfill these aims: Nanogels combined with nanoparticles or with liposomes, and involving polyethylene glycol chains or zwitterionic polymers.Entities:
Keywords: PEGylation; biocompatible carriers; drug delivery; nanogels; nanohybrids; nanolipogels.; stealth nanoparticles; zwitterionic polymers
Year: 2019 PMID: 30736486 PMCID: PMC6409538 DOI: 10.3390/pharmaceutics11020071
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Common hybrid nanogels morphologies: (a) Nanoparticle as the core, encapsulated by the nanogel shell; (b) core-shell with nanoparticle homogeneously located in the nanogel core and surrounded by a polymeric shell; and (c) polymer network assembled in core-layer-shell structure. (Artwork not drawn to scale, the sizes for nanoparticles or nanogels range from 50 to 400 nm).
The main morphologies of the described nanogels with summarized the biological outcomes.
| Schematized Structure of the Hybrid | Stealth Strategy | Size | Biological Results | Reference |
|---|---|---|---|---|
|
| PEG chains | 80 nm a | In vitro: no toxicity on HuH-7 (50 μg/mL), HeLa (480 µg/mL) 1 | [ |
|
| PEG shell (500–4000 Da) | 52–350 nm a | (see note 2) | [ |
|
| PEG gel (300 Da), | 25–40 nm a | In vitro: no toxicity on B16F10 mouse melanoma cells (450 μg/mL) | [ |
|
| PEG/chitosan gel, | 120 nm a (pH 7.4) | In vitro: no toxicity on DU145 cells (100 μg/mL) | [ |
|
| PEG shell (5000 Da) | 90 nm a (pH 7.4) | In vitro: no toxicity on A2780 cells (5 mg/mL) | [ |
|
| PEGylated liposome (2000 Da), bioresorbable gel | 120 nm a | In vitro: only release tests in phosphate buffer (pH 7.4) | [ |
|
| PEGylated liposome | 225 nm a | In vitro: only internalization tests on CD4 T cells | [ |
|
| PEGylated liposome (4000 Da), biocompatible gel | 300 nm a | In vitro: no toxicity on NIH3T3 mouse fibroblasts (100 μg/mL) | [ |
|
| PEGylated liposome | 106 nm a | In vitro: no toxicity on 4T1 murine cancer cells (1000 μg/mL), hemocompatibility on human blood (100 μg/mL) | [ |
|
| Zwitterionic polymer: carboxybetaine, reduction-sensitive crosslinker | 110 nm a | In vitro: no cytotoxicity on macrophages (RAW264.7) and HUVEC cells (iron content: 30 ppm) 3 | [ |
|
| Zwitterionic polymer: carboxybetaine, softness of the structure | 120 nm a | In vitro: no uptake from macrophage cells (5 ppm of Au, corresponding to 42 μg/mL of nanogel) | [ |
|
| Zwitterionic polymer: ornithine | 114 nm a | In vitro: 90% viability on NIH/3T3 fibroblasts (1000 μg/mL), no protein bonded after incubation in protein solution | [ |
1 Polyethylene glycol chains of 7200 Da and toxicity on HeLa are referred to in Reference [75]. 2 Even in the absence of biological data, this work has been considered relevant for the reported characterization data. 3 Authors do not state the iron content per mg of nanogel. a Measured by dynamic light scattering. b Measured by electronic microscopy.
Figure 2Structure of hybrid PEGylated nanogel prepared by in situ self-reduction of HAuCl4.
Figure 3The PEGylated nanogel containing gold nanoparticles and fluorescein isothiocyanate-labeled peptides.
Figure 4Transmission Electron Microcopy images of the nanogel: (a) The nanoparticle before the presence of Au, trough the staining with phosphotungstic acid is revealed in the core-structure (the further outer dark layer is attributed to initiator residues) and (b) after the in-situ generation of Au nanoparticles (without staining). Reprinted from Reference [76] by permission of the publisher (Taylor and Francis Ltd, http://www.tandfonline.com), Copyright 2017 Taylor & Francis Group.
Figure 5The hybrid nanogel prepared by Zhou [77]: (a) Schematic representation and (b) TEM image which evidenced the shell thickness. Image (b) reprinted from Reference [77] Copyright (2011), with permission from Elsevier.
Figure 6Graphic representation of PEG-chitosan-(carbon dots) hybrid nanogel [78].
Figure 7Structure of the nanogel micelles [30] with the expected core-layer-shell framework to host the different drugs.
Figure 8Overall structure of the nanolipogel with the different components and the preparation steps. The cyclodextrin-methacrylate is represented as a hollow cylinder that hosts the transforming growth factor-β inhibitor SB505124 (blue sphere). Adapted by permission from Springer Nature: Nature Materials [79], Copyright 2012.
Figure 9In vivo biodistribution data: (a) Persistence in the blood stream of free and loaded rhodamine (### denotes P < 0.01 in the two population t-test); (b) cumulative biodistribution of free and loaded rhodamine (the legend denotes the post-injection hours); and (c) accumulation of rhodamine (delivered by the nanolipogel) in the tumoral tissue and residual amount in the peritumoral region. Error bars in all plots represent ± std. dev. Reprinted by permission from Springer Nature: Nature Materials [79], Copyright 2012.
Figure 10The PEGylated nanolipogel containing heparin-pluronic nanogel loaded with RNase. Adapted by permission from Springer Nature: Macromolecular Research [81], Copyright 2015.
Figure 11The nanolipogel preparation strategy with the inhibition of polymerization outside the vesicle. Note: the radical inhibitor is a TEMPO-PEG-TEMPO molecule. Adapted with permission from Reference [82]. Copyright (2018) American Chemical Society.
Figure 12TEM image of the nanolipogel prepared by Zhang and coworkers. Reprinted with permission from Reference [82]. Copyright (2018) American Chemical Society.
Figure 13Schematic passages for the preparation of zwitterionic hybrid nanogel. Reprinted from Reference [83], Copyright (2011), with permission from Elsevier.
Figure 14Zwitterionic stiff/soft nanogel: (a) Structure of the zwitterionic crosslinker; (b) a simple filtration reveal the qualitatively different behavior of the two nanogels; and (c) scanning electron microscopy image of the soft nanogel particles (scale bar = 1 μm). Reprinted with permission from Reference [84]. Copyright 2012 American Chemical Society.
Figure 15Monomer structure and zwitterionic nanogel-carbon dots assembly. Reprinted from Reference [85], Copyright (2016), with permission from Elsevier.